Lupin Is Confident Of Achieving 18% Margins By Q4, Says CFO Ramesh Swaminathan
Lupin reported first-quartr net profits of Rs 452 crore, compared with a net loss of Rs 89 crore a year earlier.
Lupin Ltd. is confident of achieving an operating margin of 18% by the fourth quarter or earlier, as guided earlier, according to Chief Financial Officer Ramesh Swaminathan.
The company reported net profits of Rs 452 crore in the June quarter, compared with a net loss of Rs 89 crore a year earlier, according to an exchange filing. That compares with Bloomberg's consensus estimate of Rs 258 crore in profit.
Revenue is up 29% at Rs 4,814 crore. (Bloomberg estimate: Rs 4,441 crore.)
Ebitda is up 422% at Rs 856 crore. (Bloomberg estimate: Rs 686 crore in profit.)
Margins at 17.8% vs. 4.4% (Bloomberg estimate: 15.4%)
According to him, three factors contributed to the topline, gross margins, and bottom line performance:
A strong growth in the India business of 10%, despite a negative impact on certain drugs on the domestic front due to inclusion under the National List of Essential Medicines.
The launch of the generic version of Prezista, Darunavir, with an exclusivity of 180 days in the U.S. despite a drop in seasonal products sequentially
A one-time milestone payment to the tune of Rs 205 crore was received from Abbie. 1.6% of the gross margin expansion was on account of the one-time payment.
This is despite higher R&D spends, some one-time expenses on testing certain products, and a business settlement.
Margin Support
"In the coming quarters, we expect newer products—gSpiriva launches—and that's going to step up our margins. The guidance of 18% certainly stays, and we are fairly confident that we would be in a position to exceed it also," Swaminathan told BQ Prime.
Swaminathan said the company expects to launch gSpiriva, its bigger launch, in the second quarter, and there will be a couple of other smaller launches that will support Lupin's margin growth even after the loss of Darunavir's 180-day exclusivity.
India's business, he said, grew on account of strong momentum in cardiovascular, diabetes, respiratory, and newer therapies like "gastrointestinal and women's health which are potentially growth areas".
US Price Erosion And Expansion Plans
On price erosion, he said that there is less competition and drug shortages, which would lead to price stabilisation. "Erosion is stabilising at high single-digit numbers." He said that they benefited in the U.S. market from a drug shortage in the acute therapy portfolio.
The focus is on India, he said while speaking about acquisition. He said the company is also looking at strategic buying, like an U.S. specialty.
On the R&D front, he said that the overall expense as a percentage of sales will keep going down, but the absolute numbers will be around the current range.
Watch the full interview here.
